KIA
BCRX icon

KCM Investment Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

KCM Investment Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-25,000
Closed -$119K – 320
2020
Q2 		$119K Buy
+25,000
New +$99.8K 0.01% 333
2014
Q3 		– Sell
-36,261
Closed -$462K – 503
2014
Q2 		$462K Hold
36,261
– – 0.04% 330
2014
Q1 		$384K Hold
36,261
– – 0.04% 333
2013
Q4 		$276K Hold
36,261
– – 0.03% 382
2013
Q3 		$264K Hold
36,261
– – 0.03% 383
2013
Q2 		$56K Buy
+36,261
New +$62.5K 0.01% 416

Other funds holding BCRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCM Investment Advisors's BCRX Position: Q3 2020 in Review

KCM Investment Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2020, closing a stake of 25,000 shares — an estimated $119K sold.

KCM Investment Advisors first reported a position in BCRX in Q2 2013 and held it in 6 quarters. The position peaked at $462K in Q2 2014. 154 funds tracked by Wall St. Rank hold BCRX as of Q3 2020.

  • KCM Investment Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • KCM Investment Advisors sold 25,000 BioCryst Pharmaceuticals shares in Q3 2020, an estimated $119K.
  • KCM Investment Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • KCM Investment Advisors's BioCryst Pharmaceuticals position peaked at $462K in Q2 2014.
  • 154 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2020.

Based on KCM Investment Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.